ECSP034866A - Combinaciones antineoplásticas - Google Patents

Combinaciones antineoplásticas

Info

Publication number
ECSP034866A
ECSP034866A EC2003004866A ECSP034866A ECSP034866A EC SP034866 A ECSP034866 A EC SP034866A EC 2003004866 A EC2003004866 A EC 2003004866A EC SP034866 A ECSP034866 A EC SP034866A EC SP034866 A ECSP034866 A EC SP034866A
Authority
EC
Ecuador
Prior art keywords
antineoplastic combinations
antineoplastic
combinations
neoplasms
treatment
Prior art date
Application number
EC2003004866A
Other languages
English (en)
Inventor
James Joseph Gibbons Jr
Gary Dukart
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP034866A publication Critical patent/ECSP034866A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Esta invención provee el uso de una combinación de un inhibidor motor y un agente de alquilación antineopláticos en el tratamiento de neoplasmas
EC2003004866A 2001-06-01 2003-11-27 Combinaciones antineoplásticas ECSP034866A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29523601P 2001-06-01 2001-06-01

Publications (1)

Publication Number Publication Date
ECSP034866A true ECSP034866A (es) 2004-01-28

Family

ID=38181186

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004866A ECSP034866A (es) 2001-06-01 2003-11-27 Combinaciones antineoplásticas

Country Status (4)

Country Link
US (2) US20020198137A1 (es)
AR (1) AR034071A1 (es)
EC (1) ECSP034866A (es)
ZA (2) ZA200603888B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
ZA200603888B (en) * 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
EP1615640B1 (en) * 2003-04-22 2007-01-24 Wyeth Antineoplastic combinations
AR046194A1 (es) * 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
ZA200706804B (en) 2005-02-03 2008-10-29 Gen Hospital Corp Method for treating gefitinib resistant cancer
KR101354828B1 (ko) 2005-11-04 2014-02-18 와이어쓰 엘엘씨 ｍＴＯＲ 저해자, 헤르셉틴, 및/또는 ＨＫＩ-272의항신생물성 조합
DE102006011507A1 (de) * 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
CA2645278A1 (en) * 2006-04-05 2007-10-25 Novartis Ag Combinations of therapeutic agents for treating cancer
US20080045589A1 (en) * 2006-05-26 2008-02-21 Susan Kelley Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CA2725598C (en) 2008-06-17 2013-10-08 Wyeth Llc Antineoplastic combinations containing hki-272 and vinorelbine
MX2011001318A (es) 2008-08-04 2011-03-04 Wyeth Llc Combinaciones antineoplasicas de 4-anilino-3-cianoquinolinas y capecitabina.
EP2416774B1 (en) 2009-04-06 2015-11-04 Wyeth LLC Treatment regimen utilizing neratinib for breast cancer
MX2011012538A (es) * 2009-05-27 2012-02-08 Cephalon Inc Terapia de combinacion para el tratamiento del mieloma multiple.

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) * 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5321009A (en) * 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
US6150398A (en) * 1991-05-08 2000-11-21 The United States Of America As Represented By The Department Of Health And Human Services Methods for the treatment of cancer
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5286731A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5286730A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5288711A (en) * 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
ZA935112B (en) * 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
JPH09512542A (ja) * 1994-04-28 1997-12-16 メルク シヤープ エンド ドーム リミテツド Ｄ▲下４▼リセプタ拮抗剤としてのベンゾフラン誘導体
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
TW466112B (en) * 1998-04-14 2001-12-01 Lilly Co Eli Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
ZA200603888B (en) * 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
EP1615640B1 (en) * 2003-04-22 2007-01-24 Wyeth Antineoplastic combinations

Also Published As

Publication number Publication date
US20060030547A1 (en) 2006-02-09
ZA200603888B (en) 2007-05-30
AR034071A1 (es) 2004-01-21
US20020198137A1 (en) 2002-12-26
ZA200309816B (en) 2006-07-26

Similar Documents

Publication Publication Date Title
ECSP056001A (es) Combinaciones antineoplásicas
CY1104983T1 (el) Αντινεοπλασματικοι συνδυασμοι
ECSP034866A (es) Combinaciones antineoplásticas
ECSP056114A (es) Combinaciones antineoplásicas
IL157898A0 (en) Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
WO2002040000A3 (en) Use of cci-779 as an antineoplastic agent
SV2005002048A (es) " combinaciones antineoplasticas de cci - 779 y rituximab " ref. am - 101608salvo
SG153647A1 (en) Antineoplastic combinations
AR033012A1 (es) Combinaciones antineoplasicas
TR200202194T2 (tr) Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri
DE60317113D1 (de) Pump- und Arbeitsfahrzeug
BRPI0208558A2 (pt) preparado de combinação de estrogênio-gestagênio e uso
CR9068A (es) Uso de un inhibidor del mtor en el tratamiento de leiomioma del utero
ES2184341T3 (es) Un metodo para la prevencion y el tratamiento de la disfuncion del miocardio.
EE05263B1 (et) IL-18 inhibiitorite kasutamine keskn„rvissteemi kahjustuste raviks v?i ennetamiseks
DE10202685B8 (de) Umlaufpumpe mit höherem Abgabedruck und Bremsvorrichtung mit derselben
AR028458A1 (es) Un estuche de combinacion usado en el tratamiento del paludismo
ECSP972265A (es) Dihidrato de d-olanzapina
IT1318562B1 (it) Uso di fosfolipidi naturali nella terapia di stati allergici.
GB0012250D0 (en) The treatment of intimal hyperplasia, and materials for use therein
ES1048887Y (es) Conjunto dispensador de infusiones de uso publico y/o privado.
ITMC20000069A0 (it) Procedimento per la sterilizzazione di fognature e locali chiusi in genere
IT1320856B1 (it) Corpo abrasivo.
ITRM20010195V0 (it) Dispositivo polifunzionale per custodia e lavaggio asetticoestemporaneo ad uso della tettarella